Karuna Therapeutics to Present Additional Data from the Phase 2 Clinical Trial of KarXT for the Treatment of Psychosis in Pat...
May 27 2020 - 6:30AM
Business Wire
Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage
biopharmaceutical company committed to developing novel therapies
with the potential to transform the lives of people with disabling
and potentially fatal neuropsychiatric disorders and pain,
announced today that data from the Phase 2 clinical trial
evaluating KarXT for the treatment of acute psychosis in patients
with schizophrenia will be presented at the American Society of
Clinical Psychopharmacology (ASCP) 2020 Annual Meeting, to be held
virtually from May 29 to May 30, 2020. The poster and oral
presentation will include new and previously reported efficacy and
safety data from the Phase 2 clinical trial.
“We look forward to presenting efficacy and safety findings from
our Phase 2 study evaluating KarXT as a potential treatment option
for schizophrenia, including additional new safety data on the
relative rates compared to placebo and time-course of treatment
emergent adverse events,” stated Steve Paul, M.D., chief executive
officer of Karuna Therapeutics. “These additional findings further
support the potential impact of addressing schizophrenia with a new
mechanism of action that has the potential to effectively treat the
condition and lessen the debilitating side effects associated with
the current standard of care.”
The accepted abstract listed below is available online on the
ASCP meeting website at https://ascp.societyconference.com. All
oral and poster presentations will be available for registered
meeting attendees during the conference.
Details of the oral presentation are as follows:
Title: KarXT (a new mechanism
antipsychotic based on xanomeline), is superior to placebo in
patients with schizophrenia: Phase 2 clinical trial results
Session Title: Pharmaceutical Pipelines Date &
Time: Saturday, May 30, 2020, 5:05 – 5:15 p.m. EDT
Presenter: Stephen Brannan, M.D., Karuna Therapeutics
The clinical findings presented at ASCP will be available on the
Events & Presentations page of Karuna’s website at
investors.karunatx.com after the conference.
About KarXT
KarXT, a proprietary oral modulator of muscarinic cholinergic
receptors, is Karuna’s lead product candidate that combines
xanomeline, a novel muscarinic agonist, with trospium, an
FDA-approved muscarinic antagonist that does not appreciably cross
the blood-brain-barrier, to preferentially stimulate muscarinic
receptors in the central nervous system (CNS). This novel product
candidate, if approved, has the potential to usher in a new
treatment paradigm and dramatically impact patients with
schizophrenia and other psychotic disorders by providing a
differentiated mechanism of action relative to current D2 dopamine
and serotonin receptor-targeting antipsychotic drugs.
About Schizophrenia
Schizophrenia is a chronic, disabling disorder typically
diagnosed in late teenage years or early adulthood. Characterized
by recurring episodes of psychosis requiring long-term treatment
with antipsychotic drugs in most patients, it affects more than 21
million people worldwide and 2.7 million Americans (0.5% - 1.0% of
U.S. population).
At least one-third of patients with schizophrenia fail to
respond to current treatments, with 74% of patients discontinuing
within 18 months of initiation. People with schizophrenia have a
10- to 15-year reduction in life expectancy and struggle to
maintain meaningful interpersonal relationships. The World Health
Organization ranks psychosis as the third-most disabling medical
condition in the world.
About Karuna
Karuna is an innovative clinical-stage biopharmaceutical company
primarily focused on developing novel therapies to address
disabling neuropsychiatric conditions characterized by significant
unmet medical need. Karuna is currently conducting a Phase 2
clinical trial of its lead product candidate, KarXT
(Karuna-Xanomeline-Trospium), for the treatment of acute psychosis
in patients with schizophrenia. Karuna also plans to initiate
clinical trials of KarXT to evaluate its potential therapeutic
benefit in other central nervous system disorders, including
psychosis in Alzheimer’s disease, as well as pain.
Forward Looking Statements
This press release contains forward looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, including statements regarding our expectations about our
cash resources, the timing of advancing of our planned clinical
trials and regulatory filings, interim trial results, our goals to
develop and commercialize our product candidates, and other
statements identified by words such as “could,” “expects,”
“intends,” “may,” “plans,” “potential,” “should,” “will,” “would,”
or similar expressions and the negatives of those terms.
Forward-looking statements are not promises or guarantees of future
performance, and are subject to a variety of risks and
uncertainties, many of which are beyond our control, and which
could cause actual results to differ materially from those
contemplated in such forward-looking statements. These factors
include risks related to our limited operating history, our ability
to obtain necessary funding, our ability to generate positive
clinical trial results for our product candidates, the timing and
scope of regulatory approvals, changes in laws and regulations to
which we are subject, competitive pressures, our ability to
identify additional product candidates, risks relating to business
interruptions resulting from the coronavirus (COVID-19) pandemic,
and other risks set forth under the heading “Risk Factors” of our
Annual Report on Form 10-K for the year ended December 31, 2019.
Our actual results could differ materially from the results
described in or implied by such forward-looking statements.
Forward-looking statements speak only as of the date hereof, and,
except as required by law, we undertake no obligation to update or
revise these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200527005178/en/
Investor Contact: Alexis Smith 518-338-8990
asmith@karunatx.com
Media Contact: Jenn Gordon GlobalHealthPR 202 587-2580
jgordon@globalhealthpr.com
Karuna Therapeutics (NASDAQ:KRTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Karuna Therapeutics (NASDAQ:KRTX)
Historical Stock Chart
From Sep 2023 to Sep 2024